ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability,
pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with
nivolumab in patients with hepatocellular carcinoma